Incyte
Incyte Corporation (Nasdaq: INCY) is a global biopharmaceutical company that discovers, develops and commercializes proprietary therapeutics. Its business focuses on hematology, oncology, and inflammation and autoimmunity, with approved medicines and clinical programs across these areas. Products include JAKAFI… From the company’s description.
In fiscal 2025, Incyte reported revenue of $5.14B, up 21.2% from fiscal 2024, and net income of $1.29B. Its operating margin was 29.5%, and operations generated $1.41B in cash. Over the twelve months to Jun 30, 2026, revenue was $5.82B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Incyte does
In the company’s own words
Incyte Corporation (Nasdaq: INCY) is a global biopharmaceutical company that discovers, develops and commercializes proprietary therapeutics. Its business focuses on hematology, oncology, and inflammation and autoimmunity, with approved medicines and clinical programs across these areas. Products include JAKAFI (ruxolitinib) for blood cancers and graft-versus-host disease, OPZELURA (ruxolitinib) cream for skin conditions, and medicines including PEMAZYRE, ICLUSIG, MONJUVI/MINJUVI, ZYNYZ and NIKTIMVO. Incyte sells products directly in some markets and collaborates with other pharmaceutical companies to develop and commercialize medicines in others; partners include Novartis and Eli Lilly. The company also conducts drug discovery and clinical development, including programs in targeted oncology, myeloid diseases and dermatology. Its commercialized products are distributed through specialty and retail pharmacies, hospitals, distributors and wholesalers, depending on the market. Incyte’s therapeutic franchises are hematology, oncology, and inflammation and autoimmunity.
Company details
- Sector
- Health Care
- Industry (SIC)
- Professional Services
- Headquarters
- WILMINGTON, DE
- Fiscal year end
- December
- CIK
- 879169
- SIC
- 8731
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Incyte — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Incyte’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Incyte and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Incyte's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Incyte's last four quarterly filings that the numbers alone won't show?”